To assess the real-world effectiveness and tolerability of tirzepatide in patients experiencing recurrent weight gain after various bariatric procedures, including both surgical and endoscopic methods.
Key Findings:
The study included 34 patients, with a mean time since bariatric procedure of 6 ± 3 years.
Maintenance doses of tirzepatide varied, with 58.8% receiving 5 mg/week.
Adverse events were monitored through active solicitation and patient reports, with specific outcomes to be detailed in future analyses.
Interpretation:
The study provides insights into the effectiveness and tolerability of tirzepatide for managing recurrent weight gain post-bariatric surgery, suggesting potential clinical applications and the need for further detailed weight loss outcome data.
Limitations:
The study was conducted at a single center, which may limit generalizability.
Economic factors influenced treatment decisions, as anti-obesity pharmacotherapy is not reimbursed in Italy.
Exclusion of patients with type 2 diabetes may affect the applicability of findings to a broader population.
The small sample size may limit the statistical power and generalizability of the findings.
Conclusion:
The study aims to evaluate tirzepatide's role in managing recurrent weight gain after bariatric surgery, highlighting the need for further research on its long-term effectiveness and safety, particularly in diverse patient populations.
by Federica Vinciguerra, Carla Di Stefano, Fabio Guccione, Claudia Degano, Stefania Nigro, Roberto Baratta, Luigi Piazza, Giuseppe Navarra, Lucia Frittitta
